Tracking every rollback, reversal, and overreach — and the path back to the America we know.
Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana to a less-dangerous drug category under federal law. The change impacts federal regulation of marijuana in dozens of states that permit medical use, though it does not fully legalize marijuana federally. This significantly alters how the drug is regulated and enforced at the federal level.
President Trump selected Erica Schwartz, former deputy surgeon general and medical doctor, to lead the Centers for Disease Control and Prevention. Schwartz, a retired rear admiral in the U.S. Public Health Service Commissioned Corps, requires Senate confirmation. The CDC has been without permanent leadership for eight months.
The Federal Trade Commission and four states filed suit against the World Professional Association for Transgender Health, alleging deceptive claims about gender-affirming care for minors. The action targets medical professionals and organizations providing transgender healthcare services. This represents a coordinated federal and state effort to restrict access to gender-affirming medical care for transgender youth.
The Trump administration froze millions of dollars in federal funding for New York's Medicaid Fraud Control Unit (MFCU), which investigates and prosecutes healthcare provider fraud and patient abuse in Medicaid facilities. The action eliminates dedicated enforcement capacity for detecting fraud and protecting vulnerable patients in state Medicaid programs. New York loses federal resources for healthcare oversight and fraud prevention affecting thousands of Medicaid beneficiaries.
The FDA appointed Katherine Szarama as acting director of the Center for Biologics Evaluation and Research, replacing Vinay Prasad. This unit regulates vaccines and biological products for human use. The leadership change may impact vaccine approval processes and biological product oversight.
President Trump signed an executive order directing the FDA to accelerate review of psychedelic drugs including ibogaine for medical treatment. The order aims to speed access to psychedelic-based therapies, particularly for treating post-traumatic stress disorder in military veterans. The reform could expand availability of these treatments to Americans seeking alternative mental health interventions.
President Trump signed an executive order to accelerate research on psychedelic drugs for treating mental health disorders. The order aims to expedite clinical trials and regulatory pathways for these substances. This could expand treatment options for Americans suffering from depression, PTSD, and other mental health conditions.
The Trump administration abruptly canceled tens of millions of dollars in federal teen pregnancy prevention (TPP) grants, prompting 79 House Democrats to demand reinstatement. The action removes funding for evidence-based programs designed to reduce teen pregnancy rates across the country. Democrats warn the cancellation will harm public health outcomes and disproportionately impact underserved communities.
HHS Secretary Robert F. Kennedy Jr. ended the CDC's FoodNet program that tracked parasitic infections including cyclospora across federal agencies. The termination suspended collaborative disease surveillance managed by the CDC, USDA, and FDA. The action removes early warning systems for foodborne parasitic outbreaks, leaving public health agencies and American consumers without coordinated infection tracking.
The Trump administration issued a final rule requiring most Medicaid beneficiaries aged 19-64 to demonstrate employment, community service participation, or enrollment in work programs to maintain eligibility. The policy expands work mandates across state Medicaid programs under authority of the One Big Beautiful Bill Act. Millions of low-income Americans face potential coverage loss if unable to meet work requirements.